Anzeige
Mehr »
Login
Dienstag, 28.05.2024 Börsentäglich über 12.000 News von 690 internationalen Medien
Das Konzept der "Goldenen Sieben" macht Profi-Investoren seit Jahren reich!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 165417 | ISIN: US6402681083 | Ticker-Symbol: ITH
Tradegate
27.05.24
20:55 Uhr
1,536 Euro
+0,026
+1,72 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
NEKTAR THERAPEUTICS Chart 1 Jahr
5-Tage-Chart
NEKTAR THERAPEUTICS 5-Tage-Chart
RealtimeGeldBriefZeit
1,4821,53308:41
1,4821,53308:00

Aktuelle News zur NEKTAR THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
10.05.Earnings call: Nektar Therapeutics optimistic on REZPEG and pipeline progress14
10.05.Nektar's (NKTR) Q1 Earnings and Revenues Surpass Estimates5
09.05.Nektar Therapeutics Q1 Loss Drops In Line With Estimates379WASHINGTON (dpa-AFX) - Nektar Therapeutics (NKTR) revealed Loss for first quarter that decreased from last year in line with the Street estimates.The company's bottom line totaled -$36.80 million...
► Artikel lesen
09.05.Nektar Therapeutics GAAP EPS of -$0.19, revenue of $21.6M3
09.05.NEKTAR THERAPEUTICS - 8-K, Current Report2
09.05.Nektar Therapeutics Reports First Quarter 2024 Financial Results63NKTR) today reported financial results for the first quarter ended March 31, 2024. Cash and investments in marketable securities at March 31, 2024 were $326.0 million as compared to $329.4 million...
► Artikel lesen
08.05.NKTR, BRFS and SEED are among premarket gainers6
24.04.Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases239Program is the Product of a Research Collaboration between Biolojic Design and Nektar entered in 2021TEL AVIV, Israel and SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- Biolojic Design, a biotechnology...
► Artikel lesen
17.04.NEKTAR THERAPEUTICS - 8-K, Current Report9
11.04.NKTR, VERU and EGIO among mid-day movers91
06.03.Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata44
05.03.NEKTAR THERAPEUTICS - 10-K, Annual Report15
05.03.Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat8
05.03.Nektar Therapeutics (NKTR) Q4 2023 Earnings Call Transcript6
05.03.Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata189SAN FRANCISCO, March 5, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a biotechnology company developing medicines for the treatment of auto-immune disorders, today announced the initiation...
► Artikel lesen
05.03.Earnings call: Nektar Therapeutics unveils drug development progress5
04.03.Nektar Therapeutics Q4 Loss decreases, but misses estimates486WASHINGTON (dpa-AFX) - Nektar Therapeutics (NKTR) released Loss for fourth quarter that decreased from last year but missed the Street estimates.The company's earnings totaled -$42.08 million...
► Artikel lesen
04.03.Nektar Therapeutics GAAP EPS of -$0.22 misses by $0.01, revenue of $23.89M beats by $2.52M7
04.03.Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results82SAN FRANCISCO, March 4, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2023. Cash and investments...
► Artikel lesen
04.03.Nektar Therapeutics Announces $30 Mln Private Placement Financing With TCGX; Stock Up In Premarket13
Seite:  Weiter >>
35 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1